RU2013131870A - METHOD FOR DETECTING AVAILABILITY, SEVERITY, RISK AND POSITION FOR RECIDIENTS, AND ALSO TREATMENT AND REACTION TO TREATMENT OF URINARY INFLAMMATION AND KITS FOR ITS DESCRIPTION - Google Patents
METHOD FOR DETECTING AVAILABILITY, SEVERITY, RISK AND POSITION FOR RECIDIENTS, AND ALSO TREATMENT AND REACTION TO TREATMENT OF URINARY INFLAMMATION AND KITS FOR ITS DESCRIPTION Download PDFInfo
- Publication number
- RU2013131870A RU2013131870A RU2013131870/15A RU2013131870A RU2013131870A RU 2013131870 A RU2013131870 A RU 2013131870A RU 2013131870/15 A RU2013131870/15 A RU 2013131870/15A RU 2013131870 A RU2013131870 A RU 2013131870A RU 2013131870 A RU2013131870 A RU 2013131870A
- Authority
- RU
- Russia
- Prior art keywords
- eosinophilic peroxidase
- detecting
- eosinophilic
- peroxidase
- sample
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5428—IL-10
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5437—IL-13
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
1. Способ обнаружения воспаления мочевыводящих путей у пациента, содержащий: а) обеспечение образца от пациента; и б) обнаружение в указанном образце экспрессии по меньшей мере одного из биомаркеров, выбранных из группы, содержащей ИЛ-33, ИЛ-13, ИЛ-10 и эозинофильную пероксидазу.2. Способ по п. 1, включающий обнаружение присутствия мРНК для ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы.3. Способ по п. 2, включающий взаимодействие указанных мРНК для ИЛ-33 и/или ИЛ-13, и/или ИЛ-10, и/или эозинофильной пероксидазы с зондом из нуклеиновой кислоты, комплементарным к указанной мРНК для ИЛ-33 и/или ИЛ-13, и/или ИЛ-10 и/или эозинофильной пероксидазы.4. Способ по п. 1, включающий обнаружение присутствия полипептидов ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы.5. Способ по п. 4, включающий взаимодействие указанных полипептидов ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы с антителом, специфичным к указанному полипептиду ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы и обнаружение связывания указанного антитела с указанным полипептидом ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы.6. Способ по п. 1, в котором испытуемым является человек.7. Способ по п. 1, где образец включает мочу, кровь, и/или клетки или ткань мочевого пузыря.8. Способ лечения обнаруженного в соответствии со способом по п. 1 воспаления мочевыводящих путей, включающий: а) обеспечение образца от исследуемого; б) обнаружение экспрессии ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы в указанном образце; в) на основании указанной экспрессии ИЛ-33 и/или ИЛ-13 и/или ИЛ-10 и/или эозинофильной пероксидазы подавление воспаления с пом1. A method for detecting inflammation of the urinary tract in a patient, comprising: a) providing a sample from the patient; and b) detecting in said sample expression of at least one of the biomarkers selected from the group consisting of IL-33, IL-13, IL-10 and eosinophilic peroxidase. 2. A method according to claim 1, comprising detecting the presence of mRNA for IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase. 3. The method of claim 2, comprising reacting said mRNA for IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase with a nucleic acid probe complementary to said mRNA for IL-33 and / or IL-13, and / or IL-10 and / or eosinophilic peroxidase. 4. A method according to claim 1, comprising detecting the presence of IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase polypeptides. The method of claim 4, comprising reacting said IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase polypeptides with an antibody specific for said IL-33 and / or IL-13 and / or IL -10 and / or eosinophilic peroxidase and detecting binding of the indicated antibody to the indicated IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase polypeptide. 6. The method of claim 1, wherein the test person is a human. The method of claim 1, wherein the sample includes urine, blood, and / or cells or tissue of the bladder. A method of treating an inflammation of the urinary tract detected in accordance with the method of claim 1, comprising: a) providing a sample from the subject; b) detecting the expression of IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase in the specified sample; c) based on the indicated expression of IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase, suppression of inflammation with
Claims (14)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013131870/15A RU2013131870A (en) | 2013-07-11 | 2013-07-11 | METHOD FOR DETECTING AVAILABILITY, SEVERITY, RISK AND POSITION FOR RECIDIENTS, AND ALSO TREATMENT AND REACTION TO TREATMENT OF URINARY INFLAMMATION AND KITS FOR ITS DESCRIPTION |
PCT/RU2014/000422 WO2015005823A1 (en) | 2013-07-11 | 2014-06-06 | Methods for detecting, treating and preventing urinary tract inflammation/infection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013131870/15A RU2013131870A (en) | 2013-07-11 | 2013-07-11 | METHOD FOR DETECTING AVAILABILITY, SEVERITY, RISK AND POSITION FOR RECIDIENTS, AND ALSO TREATMENT AND REACTION TO TREATMENT OF URINARY INFLAMMATION AND KITS FOR ITS DESCRIPTION |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2013131870A true RU2013131870A (en) | 2015-01-20 |
Family
ID=52280356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013131870/15A RU2013131870A (en) | 2013-07-11 | 2013-07-11 | METHOD FOR DETECTING AVAILABILITY, SEVERITY, RISK AND POSITION FOR RECIDIENTS, AND ALSO TREATMENT AND REACTION TO TREATMENT OF URINARY INFLAMMATION AND KITS FOR ITS DESCRIPTION |
Country Status (2)
Country | Link |
---|---|
RU (1) | RU2013131870A (en) |
WO (1) | WO2015005823A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2115124C1 (en) * | 1994-05-17 | 1998-07-10 | Михаил Иосифович Коган | Method of diagnosis of pyelonephritis acute stage |
RU2153672C1 (en) * | 1999-10-22 | 2000-07-27 | Московский областной научно-исследовательский клинический институт | Method for performing differential diagnosis of inflammatory processes in male urogenital paths |
RU2215534C2 (en) * | 2002-01-08 | 2003-11-10 | Государственное унитарное предприятие "Иммунопрепарат" | Method for treatment of inflammatory diseases of organs of urinary system |
GB0423974D0 (en) * | 2004-10-28 | 2004-12-01 | Ares Trading Sa | Proteins |
WO2008127271A2 (en) * | 2006-09-08 | 2008-10-23 | Abbott Laboratories | Interleukin -13 binding proteins |
-
2013
- 2013-07-11 RU RU2013131870/15A patent/RU2013131870A/en not_active Application Discontinuation
-
2014
- 2014-06-06 WO PCT/RU2014/000422 patent/WO2015005823A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2015005823A1 (en) | 2015-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kim et al. | Noninvasive precision screening of prostate cancer by urinary multimarker sensor and artificial intelligence analysis | |
NZ601022A (en) | Diagnosis and treatment of cancer using anti-ereg antibody | |
JP6401702B2 (en) | Methods and compositions for diagnosis of inflammatory liver disease | |
JP2010504530A5 (en) | ||
RU2014114838A (en) | WAYS OF CONTROL OF SUSCEPTIBILITY OF ANTI-SMAD7 THERAPY | |
NO20076656L (en) | Improved immunoassay methods | |
NO20083820L (en) | Detection of cancer at elevated levels of BCL-2 | |
JP2017524130A5 (en) | ||
JP2015514227A5 (en) | ||
JP2015517801A5 (en) | ||
JP2014509515A5 (en) | ||
JP2006311860A5 (en) | ||
ES2845656T3 (en) | Kits and procedures for detecting endothelial cell antibodies in allograft rejection | |
US20200109454A1 (en) | Nourin molecular biomarkers diagnose angina patients with negative troponin | |
Caccaro et al. | Clinical utility of calprotectin and lactoferrin in patients with inflammatory bowel disease: is there something new from the literature? | |
JP2015530868A5 (en) | ||
WO2015048804A3 (en) | Protein biomarker and uses thereof | |
CN104049090B (en) | A kind of test kit detecting alanylamino peptase | |
Cho et al. | Both the sera of patients with Behçet’s disease and Streptococcus sanguis stimulate membrane expression of hnRNP A2/B1 in endothelial cells | |
KR102525734B1 (en) | Arteriosclerosis and cancer detection method using deoxyhypusine synthase gene as indicator | |
Haslene-Hox et al. | Quantification of the concentration gradient of biomarkers between ovarian carcinoma interstitial fluid and blood | |
RU2013131870A (en) | METHOD FOR DETECTING AVAILABILITY, SEVERITY, RISK AND POSITION FOR RECIDIENTS, AND ALSO TREATMENT AND REACTION TO TREATMENT OF URINARY INFLAMMATION AND KITS FOR ITS DESCRIPTION | |
WO2019170545A8 (en) | Means for the quantitative determination of an analyte concentration in a patient's urine sample | |
NZ601643A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
RU2014114138A (en) | METHOD (OPTIONS) AND KIT FOR DIAGNOSTIC OF URINARY INFECTIONS, METHOD OF TREATMENT AND PREPARATION OF URINARY INFECTIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HE9A | Changing address for correspondence with an applicant | ||
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20151028 |